Last update 01 Nov 2024

Changxing County People's Hospital

Hospital|

Zhejiang Sheng, China

Hospital|

Zhejiang Sheng, China

Last update 01 Nov 2024

Overview

Pipeline

Deal

Translational Medicine

Overview

Clinical Trials associated with Changxing County People's Hospital

NCT06218485 / Not yet recruitingNot ApplicableIIT

Comparison of Fractional Flow Reserve-Guided Strategy Versus Intravascular Ultrasound-Guided Stent Implantation After Angiography-Derived Fractional Flow Reserve-based Decision-Making (The FLAVOUR III Trial)

To compare the clinical outcomes of fractional flow reserve (FFR)-guided strategy versus intravascular ultrasound (IVUS)-guided stent implantation after angiography-derived FFR-based decision-making.

Start Date01 Mar 2024

Sponsor / Collaborator

Second Affiliated Hospital Zhejiang University School of Medicine

[+15]

NCT05923489 / RecruitingNot ApplicableIIT

Routine Angiography Follow-Up After Percutaneous Coronary Intervention in High-Risk Patients (The REVISE Trial)

Comparison of clinical outcomes between routine angiography follow-up and routine clinical follow-up after percutaneous coronary intervention in high-risk patients.

Start Date26 Oct 2023

Sponsor / Collaborator

Second Affiliated Hospital Zhejiang University School of Medicine

[+6]

ChiCTR2300070424 / SuspendedNot ApplicableIIT

The impact of therapeutic drug monitoring of carbapenems on clinical outcome in critically ill patients: A prospective, multicenter, randomized controlled study

Start Date07 Apr 2023

Sponsor / Collaborator

Changxing County People's Hospital

100 Clinical Results associated with Changxing County People's Hospital

0 Patents (Medical) associated with Changxing County People's Hospital

Literatures (Medical) associated with Changxing County People's Hospital

01 May 2024·The Clinical Respiratory Journal

Efficacy of neoadjuvant chemotherapy combined with surgery in patients with nonsmall cell lung cancer: A meta‐analysis

Review

Author: Yang, Cheng-Yan ; Dong, Hai-Jun

AbstractIntroductionThis meta‐analysis sought to investigate the effect of neoadjuvant chemotherapy (NACT) combined with surgery in patients with nonsmall cell lung cancer (NSCLC).MethodsWith time span from January 2010 to December 2022, PubMed, Web of Science and Embase, China National Knowledge Infrastructure, and WanFang databases were searched for randomized controlled trials on comparison between NACT combined with surgery and surgery alone in patients with NSCLC. Then a meta‐analysis was performed in accordance with Preferred Reporting Items for Systematic reviews and Meta‐Analyses (PRISMA) guidelines.ResultsA total of 1511 studies were retrieved and 12 were finally included. Meta‐analysis results showed that compared with surgery alone, a combination of NACT and surgery was associated with higher treatment response rate (odds ratio, OR = 2.459, 95% confidence interval, CI [1.785, 3.388], P < 0.001), 1‐year survival rate (OR = 2.185, 95% CI [1.608, 2.970], P < 0.001), and 3‐year survival rate (OR = 2.195, 95% CI [1.568, 3.073], P < 0.001) and lower levels of intraoperative blood loss (standardized mean difference, SMD = −0.932, 95% CI [−1.588, −0.275], P = 0.005) and length of hospital stay (SMD = −0.481, 95% CI [−0.933, −0.028], P = 0.037).ConclusionNACT combined with surgery is superior to surgery alone in the treatment of NSCLC and can promote postoperative recovery. Collectively, such combination is a safe and effective treatment for patients with NSCLC.

01 Apr 2024·Minerva Surgery

Comparative analysis of clinical efficacy and safety of Plavix and aspirin in the treatment of coronary heart disease

Article

Author: Hu, Changbao ; Zhang, Yehong ; Wu, Mingqiu

08 Jul 2023·Zhonghua bing li xue za zhi = Chinese journal of pathology

[Diagnostic values of nuclear score combined with cyclin D1 immunocytochemistry in indeterminate thyroid follicular nodules in preoperative fine needle aspiration].

Article

Author: Miao, G ; Liu, L T ; Chen, L ; Wang, M G ; Liu, D G ; He, S R ; Hu, S T ; Chen, R M

Objective: To assess the feasibility of nuclear score combined with cyclin D1 immunocytochemistry in classifying indeterminate thyroid nodules with fine-needle aspiration (FNA) cytological diagnosis of Bethesda category Ⅲ-Ⅴ. Methods: A consecutive cohort of 118 thyroid FNA specimens with indeterminate diagnosis (TBSRTC category Ⅲ-Ⅴ) and available histopathologic follow-up data were collected between December 2018 and April 2022 at the Department of Pathology, Beijing Hospital, China. These cases were subjected to cytological evaluation and cyclin D1 immunocytochemistry. The optimal cut-off points of a simplified nuclear score and the percentage of cyclin D1-positive cells for the diagnosis of malignancy or low-risk neoplasm were determined using the receiver operating characteristic (ROC) curves and area under the ROC curve (AUC). The specificity, sensitivity, positive predictive value (PPV) and negative predictive value (NPV) of nuclear score and cyclin D1 immunostaining were evaluated from the crosstabs based on cut-off points. The diagnostic accuracy of simplified nuclear score combined with cyclin D1 immunostaining was estimated using ROC curve analysis. Results: Nuclear grooves, intra-nuclear inclusions and chromatin clearing were more commonly found in malignancy/low-risk neoplasms than benign lesions (P=0.001, P=0.012 and P=0.001 respectively). A cut-off point of≥2 for the simplified nuclear score was sensitive for defining malignancy/low-risk neoplasm, and its PPV, NPV, sensitivity and specificity were 93.6%, 87.5%, 99.0% and 50.0% respectively. A positive cut-off point of 10% positive thyroid cells in cyclin D1 immunostaining demonstrated sensitivity of 88.5%, specificity of 100%, PPV of 100% and NPV of 53.8% for correctly detecting thyroid malignancy or low-risk neoplasm. The sensitivity and PPV of simplified nuclear score combined with cyclin D1 immunostaining were 93.3% and 100%, respectively. Both specificity and NPV were maintained at high levels (100% and 66.7%, respectively). The diagnostic accuracy of simplified nuclear score combined with cyclin D1 immunostaining in detecting thyroid malignancy/low-risk neoplasm was increased to 94.1% compared to using either of them alone. Conclusions: Combing simplified nuclear score and cyclin D1 immunostaining on FNA cytology specimens can increase the diagnostic accuracy in classifying thyroid nodules of indeterminate cytological categories. Thus, this supplementary approach provides a simple, accurate, and convenient diagnostic method for cytopathologists so that may reduce unnecessary thyroidectomies.

100 Deals associated with Changxing County People's Hospital

100 Translational Medicine associated with Changxing County People's Hospital

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 08 Jan 2025

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Changxing County People's Hospital

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 08 Jan 2025

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing